176 |
Cost Effectiveness of Endovascular Procedures - Can We Afford These Expensive Technologies? |
Mark W. Burket |
Apr. 21. 16 |
175 |
Atherectomy Followed by Drug Coated Balloon Angioplasty - Is This the Holy Grail? |
Lawrence A. Garcia |
Apr. 21. 16 |
174 |
Endovascular Therapies for Resistant Hypertension - The ROX 1 Year Results |
Krishna Rocha-Singh |
Apr. 21. 16 |
173 |
EVAR - Evolving Techniques and Devices |
Robert Bersin |
Apr. 21. 16 |
172 |
Carotid Stenting for Asymptomatic Carotid Stenosis - Will ACT 1 Change Anything? |
Richard R. Heuser |
Apr. 21. 16 |
171 |
Drug Coated Balloons for Femoropopliteal Disease - Insights from Randomized Trials and Global Registries |
John Robert Laird, Jr. |
Apr. 21. 16 |
170 |
Best Approach Using DCB, Atherectomy, DES or BVS in BTK |
Lawrence A. Garcia |
Apr. 21. 16 |
169 |
Novel Therapy in CLI as Stem Cells, Growth Factors, Are They Clinically Beneficial or Horizon Therapy? |
Krishna Rocha-Singh |
Apr. 21. 16 |
168 |
What Is the Best Angiographic Endpoint for Revascularization?(Angiosome or "Straight-Line" Flow) |
Osamu Iida |
Apr. 21. 16 |
167 |
Current and Upcoming Evidence-Based Approach in CLI: Endovascular vs. Surgery (OLIVE 3-Year and BEST-CLI Trial) |
Mark W. Burket |
Apr. 21. 16 |